Interrelationships between the kinetics of VLDL subspecies and hdl catabolism in abdominal obesity: A multicenter tracer kinetic study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages 4281-4290

  Vergès, Bruno ^a,c   Adiels, Martin ^d   Boren, Jan ^d   Barrett, Peter Hugh ^d,e   Watts, Gerald F ^e   Chan, Dick ^e   Duvillard, Laurence ^b,c   Söderlund, Sanni ^e   Matikainen, Niina ^e,f   Kahri, Juhani ^f   Robin, Isabelle ^a   Taskinen, Marja Riitta ^e  

^a Departments of Endocrinology Diabetology   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; GLYCEROL; HIGH DENSITY LIPOPROTEIN; LEUCINE; STABLE ISOTOPE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN1; VERY LOW DENSITY LIPOPROTEIN2; APOLIPOPROTEIN;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CATABOLISM; FEMALE; HUMAN; IN VIVO STUDY; INTRAABDOMINAL FAT; KINETICS; LIVER FAT; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SUBCUTANEOUS FAT; CLINICAL TRIAL; LIVER; MIDDLE AGED; MULTICENTER STUDY;

ADIPOSE TISSUE; ADULT; AGED; APOLIPOPROTEINS; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; LIVER; MALE; MIDDLE AGED; OBESITY, ABDOMINAL;

EID: 84910003711     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2365     Document Type: Article

References (27)

1. Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 1990; 10(4): 497-511.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285(19): 2486-2497.
3. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003; 52(5): 1210-1241.
4. Hong Y, Jin X, Mo J, et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality-results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med. 2007; 262(1): 113-122.
5. Després JP. Dyslipidaemia and obesity. Baillières Clin Endocrinol Metab. 1994; 8(3): 629-660.
6. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004; 109(1): 42-66.
7. Pont F, Duvillard L, Florentin E, Gambert P, Vergès B. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. Anin vivo stable isotope study. Int J Obes Relat Metab Disord J Int Assoc Study Obes. 2002; 26(9): 1151-1158.
8. Chan DC, Barrett PHR, Ooi EMM, Ji J, Chan DT, Watts GF. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab. 2009; 94(3): 989-997.
9. Ooi E, Watts G, Farvid M, et al. High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res. 2005; 13(6): 1008-1016.
10. Packard C, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arter Thromb Vasc Biol. 1997; 17(12): 3542-3556.
11. Adiels M, Taskinen M-R, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006; 49(4): 755-765.
12. Ji J, Watts G, Johnson A, et al. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J Clin Endocrinol Metab. 2006; 91(3): 973-979.
13. Adiels M, Packard C, Caslake MJ, et al. A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res. 2005; 46(1): 58-67.
14. Vakkilainen J, Jauhiainen M, Ylitalo K, et al. LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res. 2002; 43(4): 598-603.
15. Chan DC, Watts GF, Nguyen MN, Barrett PHR. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr. 2006; 84(1): 37-43.
16. Barrett PH, Bell BM, Cobelli C, et al. SAAMII: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998; 47(4): 484-492.
17. Watts GF, Barrett PHR, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 2003; 52(3): 803-811.
18. Guyard-Dangremont V, Lagrost L, Gambert P, Lallemant C. Competitive enzyme-linked immunosorbent assay of the human cholesteryl ester transfer protein (CETP). Clin Chim Acta. 1994; 231(2): 147-160.
19. Desrumaux C, Athias A, Bessède G, et al. Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol. 1999; 19(2): 266-275.
20. Chan DC, Watts GF, Barrett PHR, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002; 51(8): 2377-2386.
21. Vergès B, Florentin E, Baillot-Rudoni S, et al. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL-and LDL-ApoB kinetics in type 2 diabetes. Diabetologia. 2008; 51(8): 1382-1390.
22. Vergès B, Florentin E, Baillot-Rudoni S, et al. Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. J Lipid Res. 2009; 50(6): 1209-1215.
23. Ng TWK, Watts GF, Barrett PHR, Rye K-A, Chan DC. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome. Diabetes Care. 2007; 30(11): 2945-2950.
24. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003; 36(6): 421-429.
25. Saku K, Gartside PS, Hynd BA, Mendoza SG, Kashyap ML. Apolipoprotein AI and AII metabolism in patients with primary highdensity lipoprotein deficiency associated with familial hypertriglyceridemia. Metabolism. 1985; 34(8): 754-764.
26. Hime NJ, Barter PJ, Rye KA. Evidence that apolipoprotein A-I facilitates hepatic lipase-mediated phospholipid hydrolysis in reconstituted HDL containing apolipoprotein A-II. Biochemistry (Mosc). 2001; 40(18): 5496-5505.
27. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006; 116(12): 3090-3100.